Chimerna Therapeutics

Chimerna Therapeutics is a private biotech focused on unlocking the therapeutic potential of RNA through its innovative Tornado circularization platform. This technology allows cells to produce stable, circular RNAs that resist degradation, enabling the development of RNA aptamers, sponges, and other modalities for intracellular targets. The company is advancing its own pipeline in areas like Alzheimer's and NASH while also developing platform technologies to accelerate external drug discovery efforts, particularly in microRNA biology and recombinant protein production.

The Tornado platform is a method for generating genetically encodable, self-processing circular RNAs within cells, conferring exceptional stability and enabling high-level intracellular expression of therapeutic RNA aptamers, sponges, and other modalities.

Chimerna competes with other biotechs developing circular RNA (e.g., Orna Therapeutics) and stable nucleic acid platforms. Its differentiation is the genetically encodable, self-processing nature of the Tornado system, designed for sustained in vivo production, and its specific focus on developing intracellular RNA aptamers as protein-targeting therapeutics.